SCHEMBL289975

SCHEMBL289975

O=C(O)c1sc(Cl)nc1Cl

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.63
HPGD P15428 1/20 0.63
TSHR P16473 1/20 0.63
SMN1; SMN2 Q16637 2/20 0.37
KDM4E B2RXH2 1/20 0.37
NPC1 O15118 1/20 0.37
POLB P06746 1/20 0.37
RAB9A P51151 1/20 0.37
MCL1 Q07820 3/20 0.34
GPR35 Q9HC97 1/20 0.34
GAA P10253 1/20 0.33
HTT P42858 1/20 0.33
KMT2A Q03164 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
RXFP1 Q9HBX9 2/20 0.33
NPSR1 Q6W5P4 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
PIK3CD O00329 1/20 0.33
PIK3CA P42336 1/20 0.33
PIK3CB P42338 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Formaldehyde SCHEMBL28138631 0.96 ALDH1A1 (0.59) ALDH1A1HPGDTSHRSMN1; SMN2KDM4E
SCHEMBL27858664 0.83 ALDH1A1 (0.48) ALDH1A1HPGDTSHRSMN1; SMN2KDM4E
SCHEMBL23930493 0.82 ALDH1A1 (0.48) ALDH1A1HPGDTSHRGAAHTT
SCHEMBL9501591 0.81 ALDH1A1 (0.47) ALDH1A1HPGDTSHRSMN1; SMN2KDM4E
SCHEMBL27654995 0.79 ALDH1A1 (0.61) ALDH1A1HPGDTSHRSMN1; SMN2KDM4E
SCHEMBL29877075 0.79 ALDH1A1 (0.45) ALDH1A1HPGDTSHRSMN1; SMN2KDM4E
SCHEMBL9460236 0.79 ALDH1A1 (0.45) ALDH1A1HPGDTSHRPOLBKMT2A
SCHEMBL27259598 0.79 ALDH1A1 (0.50) ALDH1A1HPGDTSHRNPC1RAB9A
SCHEMBL13066651 0.77 ALDH1A1 (0.44) ALDH1A1HPGDTSHRSMN1; SMN2KDM4E
SCHEMBL13068840 0.77 ALDH1A1 (0.44) ALDH1A1HPGDTSHRSMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4578451-A2 COMPOUNDS AND COMPOSITIONS AS SPPL2A INHIBITORS Novartis AG (CH) 2025-07-02 EP disclosed
EP-4214210-B1 COMPOUNDS AND COMPOSITIONS AS SPPL2A INHIBITORS NOVARTIS AG (CH) 2025-04-09 EP disclosed
US-20240383856-A1 INHIBITORS OF TRANSGLUTAMINASES ZEDIRA GMBH (DE) 2024-11-21 US disclosed
EP-4192814-B1 INHIBITORS OF TRANSGLUTAMINASES ZEDIRA GMBH (DE) 2024-08-07 EP disclosed
CN-117616011-A Inhibitors of transglutaminase 策迪拉有限公司 2024-02-27 CN disclosed
US-11840529-B2 Substituted pyrimidines as LRKK2 inhibitors DENALI THERAPEUTICS INC. (US) 2023-12-12 US disclosed
US-20230365571-A1 COMPOUNDS AND COMPOSITIONS AS Sppl2a INHIBITORS NOVARTIS AG (CH) 2023-11-16 US disclosed
US-20230365571-A1 COMPOUNDS AND COMPOSITIONS AS Sppl2a INHIBITORS NOVARTIS AG (CH) 2023-11-16 US disclosed
US-20230365571-A1 COMPOUNDS AND COMPOSITIONS AS Sppl2a INHIBITORS NOVARTIS AG (CH) 2023-11-16 US disclosed
CN-116615425-A Compounds and compositions as Sppl2a inhibitors 诺华股份有限公司 2023-08-18 CN disclosed
US-20090270456-A1 Novel chemical compounds HASEGAWA MASAICHI 2009-10-29 US disclosed
CN-1058490-C Tetrazolinone derivatives BAYER AGROCHEM KK (JP) 2000-11-15 CN disclosed
EP-0695748-B1 Tetrazolinone herbicides BAYER AGROCHEM KK (JP) 1999-05-06 EP disclosed
US-5589439-A HERBICIDES NIHON BAYER AGROCHEM K.K. (JP) 1996-12-31 US disclosed
EP-0459244-B1 Sulphonilised carboxylic acid amides BAYER AG (DE) 1996-02-28 EP disclosed
EP-0695748-A1 Tetrazolinone herbicides NIHON BAYER AGROCHEM K.K. (JP) 1996-02-07 EP disclosed
EP-0569810-A1 Sulphonylamide herbicides BAYER AG (DE) 1993-11-18 EP disclosed
US-5256632-A Pre- and postemergence BAYER AKTIENGESELLSCHAFT (DE) 1993-10-26 US disclosed
US-5205853-A Premergence and postemergence herbicides BAYER AKTIENGESELLSCHAFT (DE) 1993-04-27 US disclosed
EP-0459244-A1 Sulphonilised carboxylic acid amides BAYER AG (DE) 1991-12-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230365571-A1 COMPOUNDS AND COMPOSITIONS AS Sppl2a INHIBITORS SPPL2A, SPPL2B, BACE1 ALDH1A1 3565/4885HPGD 2716/4885TSHR 4010/4885
US-11840529-B2 Substituted pyrimidines as LRKK2 inhibitors LRRK2, DTYMK, LMTK2 ALDH1A1 4020/4885HPGD 1818/4885TSHR 3907/4885
US-20090270456-A1 Novel chemical compounds HIPK3, HIPK2, HIPK1 ALDH1A1 4599/4885HPGD 3890/4885TSHR 4196/4885
US-20240383856-A1 INHIBITORS OF TRANSGLUTAMINASES TGM2, TGM3, TGM1 ALDH1A1 1825/4885HPGD 671/4885TSHR 3418/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.